NCT00624676.

Methods	Study design: parallel, single‐blind design; 80 participants in total Duration of follow‐up: 12 weeks
Participants	Inclusion criteria 18 years of age or older Phototype > grade I Facial inflammatory acne with 15 to 50 inflammatory lesions and fewer than 50 non‐inflammatory lesions Exclusion criteria Pregnant, nursing, or not using any efficient contraception History of major medical or psychiatric condition or surgical interventions, history of photosensitivity Acute or chronic disease or dermatological condition on the face other than acne Allergy to one of the constituents of the study product Using topical acne treatment, cyclins, or zinc‐based treatment, or oral isotretinoin Sites of acne: face
Interventions	Interventions in Group A Topical treatment: lipo hydroxy acid Regimen: leave‐on Concentration: 0.3% Vehicle: gel Dose: twice daily Duration: 12 weeks Interventions in Group B Topical treatment: benzoyl peroxide Regimen: leave‐on Concentration: 5% Vehicle: gel Dose: once daily Duration: 12 weeks
Outcomes	Primary outcomes of review interest None Secondary outcomes of review interest Investigator‐assessed change in lesion counts. Other outcomes reported in the study Number of events of pruritus, burning, tingling, erythema, and desquamation
Notes	This trial has been completed and is likely eligible for our review. We attempted to contact the principal investigator, Robert Bissonnette (rbissonnette@innovaderm.ca), with enquiry about availability of the full text but were unsuccessful